Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Castle Hook Partners LP

Castle Hook Partners LP lifted its position in Natera, Inc. (NASDAQ:NTRA) by 27.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,140,090 shares of the medical research company’s stock after purchasing an additional 245,505 shares during the quarter. Natera makes up 2.7% of Castle Hook Partners LP’s investment portfolio, making the stock its 11th biggest holding. Castle Hook Partners LP owned about 0.92% of Natera worth $144,734,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Covestor Ltd raised its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the last quarter. GAMMA Investing LLC raised its stake in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the last quarter. CIBC Asset Management Inc raised its stake in Natera by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 111 shares during the last quarter. RiverPark Advisors LLC raised its stake in Natera by 3.5% during the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock valued at $425,000 after acquiring an additional 112 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its stake in Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after acquiring an additional 135 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $168.45 on Thursday. The business’s fifty day moving average price is $133.88 and its two-hundred day moving average price is $119.43. The stock has a market cap of $22.24 billion, a PE ratio of -95.71 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a one year low of $53.88 and a one year high of $171.95.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the prior year, the firm earned ($0.95) EPS. Natera’s quarterly revenue was up 63.9% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on NTRA shares. BTIG Research upped their price objective on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Craig Hallum increased their target price on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen increased their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. UBS Group cut their target price on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, Piper Sandler increased their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $140.59.

Insider Transactions at Natera

In other news, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total transaction of $344,439.00. Following the sale, the insider now owns 284,741 shares in the company, valued at $36,324,409.37. This trade represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gail Boxer Marcus sold 9,682 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total value of $1,548,926.36. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,503 shares of company stock worth $6,325,804 over the last quarter. 7.60% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.